Bryce Point Capital, LLC Viridian Therapeutics, Inc.\De Transaction History
Bryce Point Capital, LLC
- $345 Billion
- Q4 2024
A detailed history of Bryce Point Capital, LLC transactions in Viridian Therapeutics, Inc.\De stock. As of the latest transaction made, Bryce Point Capital, LLC holds 44,063 shares of VRDN stock, worth $739,817. This represents 0.24% of its overall portfolio holdings.
Number of Shares
44,063Holding current value
$739,817% of portfolio
0.24%Shares
1 transactions
Others Institutions Holding VRDN
# of Institutions
192Shares Held
80.4MCall Options Held
568KPut Options Held
439K-
Black Rock Inc. New York, NY4.77MShares$80.1 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.6MShares$77.2 Million0.0% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$65.2 Million9.15% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.75MShares$63 Million3.15% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.45MShares$57.9 Million12.74% of portfolio
About Viridian Therapeutics, Inc.\DE
- Ticker VRDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,888,900
- Market Cap $670M
- Description
- Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...